NEW YORK, April 16 -- CombiMatrix announced today that it has developed a microarray based on the genome sequence information released Monday on the coronavirus thought to link to the epidemic of SARS (Severe Acute Respiratory Syndrome).
The microarrays, CombiMatrix said in a statement, were fabricated within 48 hours of publication of the genetic sequence of the coronavirus, which was identified by researchers at the Centers for Disease Control in Atlanta and at the Michael Smith Genome Sciences Center in Canada and publicly available at .
CombiMatrix scientists took the SARS sequence data and used the company's informatics systems to develop probes, and then manufacture the chips.
A company spokesman told GenomeWeb that the new tool had raised interest from a variety of clinical and research entities and talks were ongoing.
CombiMatrix is an operating group of Acacia Research of Newport Beach, Calif.